Navigation Links
Genomic Health Announces Positive Results of First Clinical Outcomes Study for Biomarker Discovery Using Next Generation Sequencing at the 2011 CTRC-AACR San Antonio Breast Cancer Symposium
Date:12/8/2011

cology (ESMO).

Physicians also use the Oncotype DX Breast Cancer test to make treatment recommendations for certain node-positive breast cancer patients.  Oncotype DX has been extensively evaluated in thirteen clinical studies involving more than 4,000 breast cancer patients worldwide, including a large validation study published in The New England Journal of Medicine and a chemotherapy benefit study published in The Journal of Clinical Oncology.

The Oncotype DX Colon Cancer test is the first multigene expression test commercially available that has been clinically validated to predict risk of recurrence in patients with stage II colon cancer.  Genomic Health collaborated with the National Surgical Adjuvant Breast and Bowel Project and Cleveland Clinic on a total of four development studies in more than 1,800 to analyze patients with stage II colon cancer.  The final gene panel was then independently evaluated in more than 1,400 stage II colon cancer patients in the QUASAR validation study.

As of September 30, 2011, more than 10,000 physicians in over 60 countries had ordered more than 230,000 Oncotype DX tests.  Genomic Health has a robust pipeline focused on developing tests to optimize the treatment of prostate and renal cell cancers, as well as additional stages of breast and colon cancers.  The company is based in Redwood City, California with European headquarters in Geneva, Switzerland.  For more information, please visit www.genomichealth.com.  To learn more about Oncotype DX tests, visit: www.oncotypedx.com and www.mybreastcancertreatment.org.

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including statements relating to t
'/>"/>

SOURCE Genomic Health, Inc.
Copyright©2010 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
3. Personalized Medicine - The Genomic Revolution in Cardiac Care
4. Virogenomics, Inc. Awarded $2 Million National Institute of Standards and Technology (NIST) Advanced Technology Program Grant to Develop Integrated Diagnostic Biosensors
5. Genomic Health Announces Preliminary Results From a Study of Oncotype DX(TM) in Node-Positive Breast Cancer Patients
6. Microarray Sequence Capture Speeds Large-Scale Resequencing of Targeted Genomic Regions
7. BiPar Genomic Biomarker Data Demonstrate Overexpression of PARP-1 Gene in Multiple Cancer Types
8. Genomic Health Announces Eight Oncotype DX(R) Studies to Be Presented at 30th Annual San Antonio Breast Cancer Symposium
9. Orion Genomics Announces the Discovery of Novel Breast Cancer Biomarkers
10. Genomic Health Announces Identification of Genes Associated With Colon Cancer Recurrence Across Multiple Studies
11. Transgenomic Announces New Contracts for Phase II Trials With Two Major Pharmaceutical Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2013)... 2013  Heska Corporation (NASDAQ: HSKA, "Heska" or the "Company"), ... today that the Company will present at the Stifel Dental ... the Le Parker Meridian hotel, 119 W. 56 th ... presentation is scheduled to begin at 2:15 p.m. Eastern Time ... Heska Corporation (NASDAQ: HSKA - News) sells ...
(Date:5/22/2013)... Conn. , May 22, 2013 /PRNewswire-iReach/ -- ... stay aligned with the latest trends and events, ... that can predict where an industry is headed ... evolve. (Photo: http://photos.prnewswire.com/prnh/20130522/CG19099 ) ... partnership with market research publisher GlobalData, offer decision ...
(Date:5/22/2013)... May 22, 2013   Accuray Incorporated (Nasdaq: ... is scheduled to present at the 2013 Jefferies Global ... on Thursday, June 6, 2013 at 1:30 p.m. EDT/10:30 ... presentation will be available online from the Investor Relations ... The webcast replay of the presentation will begin ...
Breaking Medicine Technology:Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 2Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 3Adapt, React, Evolve: Staying Ahead in the Breast Cancer Gene Testing, Solar Energy, and Oil & Gas Markets with Reliable Analytics and Actionable Insights from GlobalData's 700 Market Analysts 4
... 15 Researchers at the Barbara,Ann Karmanos Cancer ... developed a HER2 DNA vaccine that has shown ... The study was reported in the September 15 ... Association for Cancer,Research., ( http://www.newscom.com/cgi-bin/prnh/20071106/KARMANOSCANCERINSTITUTELO ,GO), ...
... women each year than all cancers combined. Although ... patients, the,unique risk factors and symptoms of female ... disease particularly challenging., Data from the WOMEN ... in WomeN presented today at the American Society ...
Cached Medicine Technology:DNA Vaccine Developed at the Karmanos Cancer Institute Fights HER2-Positive Cancers 2What is the Optimal Method of Ischemia Evaluation in WomeN: Preliminary Data from the WOMEN Study 2
(Date:5/23/2013)... children and adolescents with seizures involving the temporal ... problems and psychiatric illness, especially depression. Findings published ... Wiley on behalf of the International League Against ... evaluation for pediatric epilepsy patientsparticularly for those who ... epilepsy surgery. , Current medical evidence indicates ...
(Date:5/23/2013)... 23, 2013 CareAnyware , ... health and hospice software solutions, and Cornell University ... showed significant reductions in rehospitalization rates for clinically ... Carepath protocol incorporated into CareAnyware’s EMR system. Based ... which included a 39% reduction in rehospitalization rates ...
(Date:5/23/2013)... Lotus Valve, a second-generation transcatheter aortic valve implantation ... the first 60 patients in results from REPRISE ... device performance and low mortality at 30 days., ... but there are opportunities for improvement," explained lead ... and Professor of Medicine, Monash University, Melbourne, Australia. ...
(Date:5/23/2013)... Diego, CA (PRWEB) May 23, 2013 ... Medicus Ltd. (ASX: PME), announced today that they ... available on the Apple App Store*. When used in ... Platform, Visage Ease provides authorized healthcare providers simple mobile ... Touch iOS devices. , In addition to numerous enhancements ...
(Date:5/23/2013)... 2013 Registered Dietitian and Founder of ... today on Tatalou.com offering helpful tips for travelers who ... titled “ How to Stay Healthy While Traveling ,” ... sanitizer, when it’s safe to drink the water when ... importance of staying hydrated and how taking health supplements ...
Breaking Medicine News(10 mins):Health News:Depression common among children with temporal lobe epilepsy 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 2Health News:CareAnyware and Cornell University Partner to Help Reduce Rehospitalizations by 39% in Clinically Depressed Home Health Patients 3Health News:Second-generation TAVI device -- Lotus Valve -- shows good performance in REPRISE II 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 2Health News:Mobile Imaging Access Leaps Ahead with Visage Ease 3Health News:How to Stay Healthy While Traveling 2
... and Rainbow,Kitchen Community Services announced today that they ... Against Hunger" on Saturday, April 26, 2008.,The event ... and services, and raises public awareness about the,benefits ... participants can either walk or ride bicycles,along the ...
... April 24 Prime Therapeutics (Prime), a,thought leader ... RPh, has joined the organization as Vice President ... Pharmacy Trade Relations, Wan will focus on,developing and ... Prime,s efforts in the development of strategic pharmacy,contracts ...
... Frankfurt: I7VF), INVERNESS, Scotland, April 24 /PRNewswire-FirstCall/ - ... sheet restructuring,leaving it free of all loan note indebtedness, ... to enable it to move forward. The Company has,been ... 2005., Medical Diagnostic Innovations Ltd, a UK investment ...
... (Nasdaq: STAA ) today announced that it will ... 2008 on Tuesday, May 6, 2008,after the market close. ... Tuesday, May 6, 2008 at 5:00 p.m. Eastern Time ... The dial-in number for,the conference call is 866-250-3615 for ...
... 24 The Quigley,Corporation (Nasdaq: QGLY ) today ... the first quarter ended March 31, 2008,compared to $6.1 ... The first quarter of 2008 reflects a net sales ... compared to the first quarter,of 2007. The change during ...
... ) announced that it will release first quarter 2008,financial results on Thursday, ... The Company will host a conference call to discuss the first ... First Quarter 2008 Earnings Conference Call, ... Thursday, May 1, 2008 at 5:00 p.m. Eastern Time, Dial-in: ...
Cached Medicine News:Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 2Health News:UPMC Health Plan and Rainbow Kitchen Community Services at 'W.A.R.' to Wipe Out Hunger in Pittsburgh 3Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 2Health News:IVMD Inc. Announces Fundamental Balance Sheet Restructuring. 3Health News:STAAR Surgical Announces First Quarter 2008 Earnings Release Date and Conference Call 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 2Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 3Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 4Health News:The Quigley Corporation Reports First Quarter 2008 Results - Increases Investment in Pharmaceutical R&D Future 5
The ArthroPasser easily passes any type of suture through tissue and its smooth jaw assists in eliminating,suture fraying....
Arthrex has the most extensive offering of arthroscopic suture passing instruments,available anywhere in the world. We have speci? cally designed the function of our,instruments to work hand in hand ...
85 right angled suture passer....
45 right angled suture passer....
Medicine Products: